ReviewFrontiers in oncology2026
The glucose-6-phosphatase system in cancer: from endoplasmic reticulum glucose-6-phosphate flux to stemness, immune escape, and therapeutic vulnerability.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endoplasmic reticulum glucose-6-phosphatase (G6Pase) system, traditionally linked to hepatic and renal glucose homeostasis, is increasingly recognized as a regulator of intracellular glucose-6-phosphate (G6P) partitioning with broad relevance to cancer biology. Emerging evidence implicates its catalytic subunits (G6PC1-3) and associated transporters, particularly SLC37A4/G6PT, in redox control, calcium homeostasis, protein quality control, glycogen metabolism, autophagy, epithelial-mesenchymal transition, stemness, immune evasion, and therapy resistance. In several non-gluconeogenic cancers, elevated G6Pase-system activity is associated with aggressive phenotypes, whereas in liver and kidney, G6PC loss promotes metabolic disruption and dedifferentiation. This Review highlights how ER-directed G6P flux, rather than glucose production itself, may shape tumour behaviour and reveal context-specific therapeutic vulnerabilities. Importantly, the clinical targeting of this system remains at an early, largely preclinical stage, and the therapeutic opportunities discussed here should be regarded as hypotheses to be tested rather than established interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.